A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2016
At a glance
- Drugs Mitomycin (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms OPTIMA
- Sponsors TheraCoat; UroGen Pharma
- 01 Apr 2014 Top-line results reported in a TheraCoat media release.
- 01 Apr 2014 Status changed from recruiting to completed, as reported by a TheraCoat media release.
- 04 Mar 2013 New trial record